DCVMN International is proud to share a remarkable achievement by one of our member companies, SINERGIUM Biotech in collaboration with the Pan American Health Organization (PAHO), the Government of Argentina and Pfizer, in strengthening vaccine production and access in Latin America and the Caribbean.
A groundbreaking partnership has been announced between the PAHO, the Government of Argentina, Pfizer, and Sinergium Biotech to facilitate local production and regional access to the 20-valent pneumococcal conjugate vaccine (PCV20) reducing the burden on vulnerable populations. This collaboration marks the first use of PAHO’s pooled procurement mechanism, the Regional Fund for Vaccines, to leverage a technology transfer agreement. It underscores the critical role of regional markets in making local vaccine production sustainable.
As a Network dedicated to empowering vaccine manufacturers in developing countries, DCVMN remains committed to serving as a bridge, supporting our members in forging partnerships like these with other manufacturers, governments, and international organizations. These collaborations are essential to achieving equitable access to life-saving vaccines, ensuring health security, and building robust regional production capacities that benefit populations worldwide.
Congratulations to Sinergium Biotech, PAHO, the Government of Argentina and Pfizer in this remarkable achievement! This success sets an inspiring precedent for future initiatives to strengthen vaccine self-reliance and access across the globe.
For more information you can find PAHO’s announcement here: https://www.paho.org/es/noticias/15-1-2025-ops-argentina-pfizer-sinergium-impulsan-produccion-local-vacuna-antineumococica
